Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia

ConclusionsTimely molecular assessment at 3 months and 12 months appears to benefit patients with CML. Adherence to timely monitoring should be encouraged, especially in low ‐volume treatment centers.

Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Adi J. Klil ‐Drori, Hui Yin, Laurent Azoulay, Alexa Del Corpo, Michaël Harnois, Michel‐Olivier Gratton, Harold J. Olney, Robert Delage, Pierre Laneuville, Luigina Mollica, Lambert Busque, Sarit E. Assouline, for the Groupe Québécois de Tags: Original Article Source Type: research